Abivax Shares Rise 3.81% Over the Week in a Bearish Market

Abivax shares ended the week at €79.10, up 3.81% from the previous Monday when they traded at €76.20. This increase goes against the trend of the benchmark indices, with both the SBF 120 and the CAC 40 declining by 1.75% and 1.72% respectively over the same period. Trading volumes saw a sharp increase at the end of the week, rising from 70,466 shares on Tuesday to 146,959 on Friday, more than doubling, indicating a renewed interest from investors. Over the past twelve months, the biotechnology company's performance has reached 864.6%, a level much higher than the CAC 40's 4.73%, placing Abivax among the most successful stocks on the Paris stock exchange. This weekly momentum follows the presentation of the phase 3 ABTECT induction trial results for obefazimod, announced on October 6 at the United European Gastroenterology congress in Berlin. The pooled data from the ABTECT-1 and ABTECT-2 trials, involving 1,272 patients with moderate to severe ulcerative colitis, showed placebo-adjusted clinical response rates of 28% for patients without prior treatment failure and 34% for those who had failed a JAK inhibitor treatment. These results, deemed clinically significant by the medical community, partly explain the stock's maintenance above €79, a level that precisely corresponds to its current technical resistance.

From a technical perspective, the stock is now touching its resistance at €79.10, coinciding with its weekly closing price. This proximity to a major technical threshold occurs as the stock has advanced 16% from its 50-day moving average, set at €68.23, confirming a short-term upward trend. The even greater distance from the 200-day moving average, positioned at €23.86, illustrates the magnitude of the upward trajectory since the beginning of the year. The Chaikin Money Flow, an indicator measuring buying or selling pressure on the stock, displays a negative value of -0.21, suggesting that despite the weekly rise, capital flows remain mixed. The Bollinger Bands, currently framing the price between €65.98 and €78.22, show that the stock is moving at the upper limit of its statistical fluctuation zone, with a slight breach above the upper bound on Friday. This setup, combined with a contained monthly volatility of 10.44, translates to a controlled price expansion phase. The MACD, with its main line at 2.01 above its positive histogram at 0.77, confirms the continuation of the bullish momentum initiated in recent weeks. With a beta of 1.45, the stock amplifies market movements by 45%, which explains its relative resilience during this week when the indices declined.